177lu dota-biotin
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2013 (NCT02053324)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 177lu dota-biotin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02053324 | Phase 1 | Nov 11, 2013 | Dell'Angelo Hospital, Mestre, Leadiant Biosciences, Inc., Medical University of Vienna, University of Basel, University of Roma La Sapienza |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dell'Angelo Hospital, Mestre | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Leadiant Biosciences, Inc. | For profit | 1 | 1 | 1 | 2013 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Roma La Sapienza | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1